If we get good efficacy data you'll be wrong.
They may want to hook up with a larger company and sign a licensing deal if the data is good. (Not needing a credit raise)
As with all small cap bio, it's a risky venture
If we get good efficacy data you'll be wrong. They may want to...
-
- There are more pages in this discussion • 1,941 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)